A Real-World Study of JT001 for COVID-19

Overview

Real-world disease outcomes and safety in patients with mild to moderate COVID-19 treated with JT001

Eligibility

Inclusion Criteria:

1. Age ≥18 years old.
2. The novel coronavirus infection (COVID-19) meets at least one of the following five

   criteria

   1. Diagnosis of novel coronavirus infection; 2) Diagnosed with novel coronavirus pneumonia;
   2. The novel coronavirus nucleic acid test is positive; 4) Test positive for novel coronavirus antigen; 5) Culture positive for novel coronavirus.
   3. Patients who have not developed severe COVID-19 or died within 28 days of COVID-19 diagnosis, or who have developed severe COVID-19 or died within 28 days of COVID-19 diagnosis, were treated with deuterimodivir hydrobromide tablets or were not treated with anti-novel coronavirus before disease progression.

Exclusion Criteria:

        · Patients who have not developed severe COVID-19 or died within 28 days of COVID-19
        diagnosis, or those who have developed severe COVID-19 or died within 28 days of COVID-19
        diagnosis, received the following anti-novel coronavirus treatments before disease
        progression, including: Nematavir tablet/Ritonavir tablet, Azvudine tablet, Monoravir
        capsule, Zenotavir tablet/Ritonavir tablet, Leritvir tablet, Ambavirzumab/Romisivir
        injection, human immunoglobulin for COVID-19 or convalescent plasma for COVID-19 survivors.